Home > Insider Trading > Filing (0000059478-20-000187)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1821323	Sigilon Therapeutics Inc.	SGTX	Pharmaceutical Preparations (2834)	IN

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
59478	Eli Lilly & Co	Lilly Corporate Center Indianapolis IN 46285		No	No	Yes	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2020-12-08	2,444,443	$0.00	2,444,443	No	4	C	Direct
Common Stock	Acquisiton	2020-12-08	300,000	$18.00	2,744,443	No	4	P	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	C	Direct
No	4	P	Direct

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Series A-3 Convertible Preferred Stock	Disposition	2020-12-08	1,555,555	$0.00	1,555,555	$0.00
Common Stock	Series B Convertible Preferred Stock	Disposition	2020-12-08	888,888	$0.00	888,888	$0.00

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
0			No	4	C	Direct
0			No	4	C	Direct

Footnotes

Upon the closing of the Issuer's initial public offering, each share of Series A-3 Convertible Preferred Stock and Series B Convertible Preferred Stock (collectively, the "Preferred Stock") automatically converted into shares of the Issuer's common stock without payment or further consideration. There was no expiration date for the Preferred Stock. As a result of the Issuer's initial public offering, the reporting person is no longer a 10% owner of the Issuer and is therefore no longer subject to Section 16 in connection with its transactions in the equity securities of the Issuer.